Sigba, Mariel S.
HRN: 06-38-15 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
09/27/2022
CO-AMOXICLAV 625MG (TAB)
09/27/2022
10/04/2022
ORAL
625mg/tab
Q12
T/C Endometritis S/p Nsvd
Waiting Final Action
Indication: ProphylaxisEmpiric Type of Infection: Reproductive Tract Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes